Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
Tokyo, JP
ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to the research, development, production, and commercialization of medications, with a specific focus on endocrinology, obstetrics and gynecology, and urology. Within its animal health segment, ASKA manufactures, sells, imports, and exports a broad spectrum of veterinary products, such as medicines, medical equipment, animal feed and supplements, laboratory reagents, agricultural chemicals, industrial chemicals, hygiene products, and food items along with their raw materials. Beyond these activities, the company also performs clinical and biological testing and offers medical devices. Founded in 1920, ASKA Pharmaceutical Holdings Co.,Ltd. is headquartered in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.84% | -2.25% | +2.40% | +15.56% | +35.73% | +34.87% | +23.20% | +117.63% | +141.48% | +90.08% | +90.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.9% ★ Q1'26: +17.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+6.2% Q1'26: +51.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.2% Q1'26: +5.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.8% ★ Q1'26: +4.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.56× ★ Q1'26: 0.89× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
55.18B
est: 55.18B (+0.0%)
|
56.61B
est: 57.00B (-0.7%)
|
60.46B
est: 60.30B (+0.3%)
|
62.84B
est: 63.17B (-0.5%)
|
64.14B
est: 63.84B (+0.5%)
|
69.09B
69.09B – 69.09B
+8.2% YoY
|
71.07B
71.07B – 71.07B
+2.9% YoY
|
74.78B
74.78B – 74.78B
+5.2% YoY
|
75.98B
75.98B – 75.98B
+1.6% YoY
|
| EBITDA |
6.97B
est: 8.40B (-17.0%)
|
7.68B
est: 8.67B (-11.4%)
|
8.24B
est: 9.17B (-10.2%)
|
9.16B
est: 7.81B (+17.4%)
|
7.58B
est: 7.89B (-3.9%)
|
8.54B
8.54B – 8.54B
+8.2% YoY
|
8.78B
8.78B – 8.78B
+2.9% YoY
|
9.24B
9.24B – 9.24B
+5.2% YoY
|
9.39B
9.39B – 9.39B
+1.6% YoY
|
| EBIT |
3.61B
est: 5.74B (-37.1%)
|
4.80B
est: 5.92B (-19.0%)
|
5.11B
est: 6.27B (-18.5%)
|
6.50B
est: 5.53B (+17.5%)
|
5.33B
est: 5.59B (-4.6%)
|
6.05B
6.05B – 6.05B
+8.2% YoY
|
6.22B
6.22B – 6.22B
+2.9% YoY
|
6.55B
6.55B – 6.55B
+5.2% YoY
|
6.65B
6.65B – 6.65B
+1.6% YoY
|
| Net Income |
2.71B
est: 2.71B (+0.0%)
|
4.29B
est: 3.99B (+7.5%)
|
4.24B
est: 4.26B (-0.5%)
|
7.55B
est: 7.41B (+1.9%)
|
5.10B
est: 5.22B (-2.2%)
|
5.20B
5.20B – 5.20B
-0.4% YoY
|
5.61B
5.61B – 5.61B
+8.0% YoY
|
3.98B
3.98B – 3.98B
-29.0% YoY
|
5.89B
5.89B – 5.89B
+47.9% YoY
|
| SGA |
21.77B
est: 18.05B (+20.6%)
|
17.96B
est: 18.64B (-3.7%)
|
19.25B
est: 19.72B (-2.4%)
|
19.44B
est: 19.45B (-0.1%)
|
18.97B
est: 19.66B (-3.5%)
|
21.27B
21.27B – 21.27B
+8.2% YoY
|
21.88B
21.88B – 21.88B
+2.9% YoY
|
23.03B
23.03B – 23.03B
+5.2% YoY
|
23.39B
23.39B – 23.39B
+1.6% YoY
|
| EPS |
95.63
est: 95.70 (-0.1%)
|
151.22
est: 140.80 (+7.4%)
|
150.08
est: 150.30 (-0.1%)
|
266.49
est: 260.91 (+2.1%)
|
179.95
est: 183.77 (-2.1%)
|
183.10
183.10 – 183.10
-0.4% YoY
|
197.80
197.80 – 197.80
+8.0% YoY
|
140.35
140.35 – 140.35
-29.0% YoY
|
207.60
207.60 – 207.60
+47.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.06% | 404.3K | 0.24% |
| 2 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.06% | 224.4K | 0.58% |
| 3 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.05% | 173.4K | 0.31% |
| 4 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 196.0K | 0.40% |
| 5 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 42.0K | 0.30% |
| 6 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 587.1K | 0.06% |
| 7 | Dimensional - International Small Cap Value ETF DISV | 0.01% | 507.5K | 0.42% |
| 8 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.01% | 110.1K | 0.39% |
| 9 | Avantis International Small Cap Value ETF AVDV | 0.01% | 1.92M | 0.36% |
| 10 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.23M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Atsushi Maruo | Senior Managing Director & Representative Director | — | male |
| Fumiyoshi Yamaguchi | Managing Executive Officer and Director | — | — |
| Kiyohiko Tamura | Executive Corporate Officer & Director of Group Business Management Division | — | — |
| Maiko Mori | Managing Executive Officer and Director | — | — |
| Sohta Yamaguchi | President & Representative Director | — | — |
| Takashi Yamaguchi | Representative Director & Chairman of the Board | — | male |
| Tomoyuki Hatakeyama | Director of Finance & Accounting Dept., Group Bus. Mgmt Div. and Manager of Accounting Section | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4886.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
